Which is better, Wegovy or Zepbound?

For anything other than weight alone, the labels answer it and they answer it in opposite directions. Zepbound is the only drug in this category indicated for moderate-to-severe obstructive sleep apnoea with obesity. Wegovy is the only one of the two indicated to reduce major adverse cardiovascular events, the only one indicated for noncirrhotic MASH, the only one approved from age 12, and the only one with a tablet. For weight alone, the honest answer is that there is no trial of Wegovy against Zepbound. SURMOUNT-5 randomised 751 adults to "the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg)" and reported −20.2% against −13.7% at 72 weeks — a molecule comparison, open-label, funded by the manufacturer of the winning drug, with part of the semaglutide arm below Wegovy's maintenance dose.

Does Zepbound really cause less nausea than Wegovy?

Less than the raw numbers suggest and probably not less in any way the labels establish. The Wegovy label reports nausea in 44% against 16% on placebo; Zepbound reports 28% at 15 mg against 8% on placebo. About half the apparent gap is the gap between the two placebo arms, which is a fact about the trial populations rather than the drugs. On the one measure both labels report identically — any gastrointestinal adverse reaction — the excess over placebo is 26 points on both, and the proportion who discontinued because of it is 4.3% on both at the top dose. The real asymmetry is that the Zepbound label adds that the reactions "decreased over time" and no semaglutide label makes that claim.

Is the Wegovy FlexTouch cheaper than the single-dose pens?

This page will not say, because the file it uses does not price it. The CMS NADAC file dated 2026-09-16 contains rows for every Wegovy single-dose pen strength and for the Wegovy tablets, and no row for the 9.6 mg/3 mL FlexTouch. For Zepbound the comparison can be made and it is large: a month at 15 mg is $1,139 in single-dose pens and $728 from a KwikPen. It would be reasonable to expect a four-dose Wegovy device to behave similarly, and expecting is not the same as knowing, so the figure is left blank rather than estimated from the pen rate.

Can a teenager take either of these?

Wegovy injection, yes; Zepbound, no. Wegovy is indicated "to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity". Zepbound's Use in Specific Populations section contains a single sentence on the question: "The safety and effectiveness of ZEPBOUND have not been established in pediatric patients." That is not a soft signal or a matter of prescriber discretion over dose — there is no paediatric Zepbound data in the label at all, and for an adolescent the two products are not alternatives.

Is 2.4 mg of Wegovy the same as 15 mg of Zepbound?

They are both the top of their own ladder and that is the only sense in which they correspond. No label, trial or guideline states a milligram equivalence between semaglutide and tirzepatide, and the ratio between the two ladder tops is an artefact of two companies picking round numbers. Both take the same 21 weeks to climb, if you climb all the way: Wegovy reaches 2.4 mg at week 17 and the 7.2 mg high dose at week 21, while Zepbound reaches 15 mg at week 21 at the earliest. If you switch, the new product starts at its own starting dose and nothing about your old dose carries across.

Can I get Zepbound in a vial and Wegovy in a vial?

Zepbound yes, Wegovy no. The Zepbound How Supplied section lists "4 pre-filled single-dose pens, 1 single-dose vial, 4 single-dose vials, 1 multi-dose vial, or 1 single-patient-use KwikPen". The Wegovy section lists "4 single-dose pens, 4 single-dose syringes with integrated needles, or 1 single-patient-use pen (WEGOVY FlexTouch)" — pens and prefilled syringes, no vial of any kind. If you have been offered a vial of semaglutide it is not branded Wegovy, and whether it is a legitimate product at all is a different question with a different answer.

Do both carry the same warning?

The boxed warning is the same on both: the risk of thyroid C-cell tumours seen in rodents, with a contraindication in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Below the box the lists diverge in detail rather than in kind — pancreatitis, gallbladder disease, acute kidney injury from dehydration, hypoglycaemia with insulin secretagogues, and the shared instruction that neither should be combined with any other GLP-1 receptor agonist. Both labels also state that the escalation schedule exists specifically "to reduce the risk of gastrointestinal adverse reactions", which is the reason not to rush it.

Head to head

Wegovy vs Zepbound

Two branded weight-loss injections. What separates them is not mainly the molecule — it is which conditions each label covers, who is old enough to take it, and what device the drug arrives in.

Reviewed September 2026

The short answer

The decisive differences between these two are on the front page of each label, not in the pharmacology. Zepbound is indicated "to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity" and nothing else in this category is. Wegovy is indicated to reduce major adverse cardiovascular events in adults with established CV disease, and for noncirrhotic MASH with F2–F3 fibrosis under accelerated approval. If you have one of those three conditions, the label has largely chosen for you — and so, usually, has your insurer.

Age is the other threshold, and it is absolute rather than a matter of judgement. Wegovy injection covers "adults and pediatric patients aged 12 years and older with obesity". Zepbound's section 8.4 is one sentence long: "The safety and effectiveness of ZEPBOUND have not been established in pediatric patients." For a sixteen-year-old there is currently one of these two products, not two.

The second thing that decides the month is the box. Zepbound is supplied as single-dose pens, single-dose vials, multi-dose vials and a four-dose KwikPen, at all six strengths. Wegovy is supplied as single-dose pens, single-dose syringes, and one four-dose device — the FlexTouch — which exists at 2.4 mg only and has no vial equivalent. In the 2026-09-16 NADAC file, a month of Zepbound 15 mg in single-dose pens is $1,139 and the same dose from a KwikPen is $728. There is no WEGOVY FlexTouch row in that file, so this page does not say what it costs.

On side effects the raw percentages mislead and the corrected ones are identical. Nausea reads 44% for Wegovy and 28% for Zepbound 15 mg — but the placebo arms were 16% and 8%, so roughly half the apparent gap is a difference between two trial populations. On the one composite both labels report the same way, any gastrointestinal adverse reaction, the excess over placebo is 26 points on both. What is genuinely asymmetric is four words: Zepbound's label says the reactions "decreased over time" and Wegovy's does not say it or anything like it.

2 of 15 dimensions are materially the same. They are marked below rather than dressed up as differences.

Wegovy

WEGOVY injection · WEGOVY FlexTouch · WEGOVY tablets

Novo Nordisk's semaglutide product for weight management, and the only one of the two with a cardiovascular indication, a liver indication, an adolescent indication and a tablet.

Dosing protocol →

Zepbound

ZEPBOUND injection · Zepbound KwikPen

Eli Lilly's tirzepatide product for weight management, and the only drug of any kind approved in the US for moderate-to-severe obstructive sleep apnoea with obesity.

Dosing protocol →

Side by side

Every row carries how well supported it is. A claim that only reflects common practice is labelled as such rather than presented as fact.

Dimension	Wegovy	Zepbound	Basis
Obstructive sleep apnoea	Not indicated	Indicated — moderate to severe OSA in adults with obesity	labelZepbound, verbatim: "to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity." No semaglutide label carries it. Zepbound's OSA maintenance doses are narrower than its weight ones — 10 and 15 mg against 5, 10, 15 mg.
Cardiovascular risk reduction	Indicated — established CV disease with obesity or overweight	Not indicated	labelWegovy, verbatim: "to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight." Zepbound carries no CV indication; Mounjaro, the other tirzepatide brand, is a different product with a different label.
Liver disease	Indicated — noncirrhotic MASH, F2 to F3 fibrosis	Not indicated	labelOn the Wegovy label under accelerated approval, and the label says so: "This indication is approved under accelerated approval based on improvement of MASH and fibrosis… Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial." That caveat travels with the indication.
Minimum age	12 years and older (injection, obesity)	Adults only	labelWegovy injection: "adults and pediatric patients aged 12 years and older with obesity". Zepbound section 8.4, in full: "The safety and effectiveness of ZEPBOUND have not been established in pediatric patients." A hard threshold rather than a clinical judgement, and it decides the question for adolescents.
Devices in the box	Single-dose pens, single-dose syringes, one four-dose FlexTouch	Single-dose pens, single-dose vials, multi-dose vials, four-dose KwikPen	labelWegovy How Supplied: "cartons containing 4 single-dose pens, 4 single-dose syringes with integrated needles, or 1 single-patient-use pen (WEGOVY FlexTouch)". Zepbound: "cartons containing 4 pre-filled single-dose pens, 1 single-dose vial, 4 single-dose vials, 1 multi-dose vial, or 1 single-patient-use KwikPen". Zepbound has a vial and Wegovy does not — which matters for anyone drawing doses with a syringe.
The four-dose device	FlexTouch — 2.4 mg only	KwikPen and multi-dose vial — all six strengths	labelWegovy: "9.6 mg/3 mL (3.2 mg/mL) solution in a single-patient-use pen (WEGOVY FlexTouch) that delivers four 2.4 mg/0.75 mL doses". It is a maintenance-only device; you cannot escalate on it. Zepbound offers a four-dose presentation at 2.5, 5, 7.5, 10, 12.5 and 15 mg, so the whole ladder can be climbed on it. Both are preserved formulations — phenol in each — where the single-dose versions are not.
What a pharmacy paid, per month	$1,415 at 2.4 mg, $1,412 at 7.2 mg — single-dose pens	$1,139 single-dose pens, $728 KwikPen — 15 mg	literatureCMS NADAC, file dated 2026-09-16: invoice cost to a retail pharmacy, not a retail price, a cash price or a copay. The device moves the Zepbound figure by more than any clinical difference between the two drugs. There is NO WEGOVY FLEXTOUCH ROW in that file, so whether Wegovy's four-dose device produces a comparable saving is not stated here — the pen rate is not a proxy for it.
Label says the gut effects ease off	No — the sentence stops at escalation	Yes — "and decreased over time"	labelZepbound, verbatim: "The majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time." Wegovy's nearest sentence ends four words earlier: "These reactions were most frequently reported during dosage escalation." Verified by string search of both SPLs on 2026-09-20 — the phrase occurs once in the Zepbound label and zero times in the Wegovy label. "It gets better" is a labelled claim for one of these products and is not one for the other.
Nausea, weight-management pool	44% vs 16% placebo	28% vs 8% placebo at 15 mg	labelTwo separate pooled analyses, so the raw figures are not a head-to-head. The excess over placebo — 28 points against 20 — is closer than the headline, and the gap between the two placebo arms accounts for about half the apparent difference.
Any GI reaction, excess over placebosame	26 points (73% vs 47%)	26 points (56% vs 30%)	labelIdentical to the point, from two trial pools whose background rates are 17 points apart. It is the single best argument against reading the raw nausea percentages across from one label to the other.
Stopped for a GI reaction	4.3% vs 0.7% placebo	4.3% at 15 mg, 1.9% at 5 mg	labelThe proportion who actually gave up because of their gut. At each label's top weight-management dose it is 4.3% on both — but Zepbound publishes the figure by dose and it more than doubles across its own ladder, which Wegovy's single-arm table cannot show.
Escalation to the top dose	Week 17 at 2.4 mg; week 21 at 7.2 mg	Week 21 at 15 mg	labelBoth ladders take 21 weeks to reach their top. Wegovy is at an ordinary maintenance dose from week 17 and only climbs to 7.2 mg after a further 4 weeks; every Zepbound rung from 5 mg up is already a maintenance option. The milligram figures do not convert between the two molecules and nothing here converts them.
Oral version of the same brand	Yes — WEGOVY tablets, 25 mg daily	None	labelThe Wegovy SPL covers injection and tablets in one document, with the tablets indicated for weight reduction and CV risk reduction in adults. There is no oral tirzepatide of any kind, under any brand, and anything sold as one is not what it claims to be.
Boxed warningsame	Thyroid C-cell tumours	Thyroid C-cell tumours	labelThe same rodent finding and the same contraindication on both: personal or family history of medullary thyroid carcinoma, or MEN 2. Nothing in this comparison turns on it.
Head-to-head weight result	13.7% at week 72 — semaglutide arm	20.2% at week 72 — tirzepatide arm	literatureSURMOUNT-5, 751 adults with obesity and without diabetes. Read what it actually compared: participants received "the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg)", so part of the semaglutide arm never reached Wegovy's maintenance dose. It is a molecule trial, open-label, funded by Eli Lilly — not a trial of Wegovy against Zepbound. This page cites no cross-trial weight comparison of any kind.

label: Stated on the FDA label
guideline: Clinical practice guideline
literature: Published literature
practice: Common practice, not documented

Which one

Choose Wegovy if

You are 12 to 17. Wegovy injection is the only one of the two with a paediatric indication, and Zepbound states plainly that it has none.
You have established cardiovascular disease with obesity or overweight, or noncirrhotic MASH with F2–F3 fibrosis. Both are Wegovy indications and neither is on the Zepbound label.
You want or may want an oral option later. Wegovy tablets exist; no oral tirzepatide does.
It is what your plan covers. For most people this decides it, and letting it decide is reasonable when the clinical case is as close as it is here.

Choose Zepbound if

You have moderate-to-severe obstructive sleep apnoea with obesity. That is a Zepbound indication and no other drug in this category carries it.
You want the label that actually states the gut effects settle down. Only Zepbound says "decreased over time".
Cost is close to acquisition and you can get a four-dose KwikPen or multi-dose vial. The device gap on Zepbound is larger than any clinical gap between the two brands, and the equivalent Wegovy saving is not something this page can price.
You want a vial rather than a pen, for any reason. Zepbound is supplied in vials at every strength and Wegovy is not supplied in vials at all.

Strip out the indications and the devices and these two products are closer than the marketing suggests: the same boxed warning, the same 21 weeks to the top of the ladder, the same excess of gastrointestinal reactions over placebo to the percentage point, and the same 4.3% who stop because of them at the top dose. What this page will not do is rank them on weight by subtracting one brand's trial from the other's — those trials ran years apart in different populations with placebo arms that differed by more than a point on their own. The one head-to-head that exists is a molecule trial in which part of the semaglutide arm was dosed below Wegovy's maintenance dose, and it is reported here as exactly that.

Frequently asked questions

Which is better, Wegovy or Zepbound?: For anything other than weight alone, the labels answer it and they answer it in opposite directions. Zepbound is the only drug in this category indicated for moderate-to-severe obstructive sleep apnoea with obesity. Wegovy is the only one of the two indicated to reduce major adverse cardiovascular events, the only one indicated for noncirrhotic MASH, the only one approved from age 12, and the only one with a tablet. For weight alone, the honest answer is that there is no trial of Wegovy against Zepbound. SURMOUNT-5 randomised 751 adults to "the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg)" and reported −20.2% against −13.7% at 72 weeks — a molecule comparison, open-label, funded by the manufacturer of the winning drug, with part of the semaglutide arm below Wegovy's maintenance dose.
Does Zepbound really cause less nausea than Wegovy?: Less than the raw numbers suggest and probably not less in any way the labels establish. The Wegovy label reports nausea in 44% against 16% on placebo; Zepbound reports 28% at 15 mg against 8% on placebo. About half the apparent gap is the gap between the two placebo arms, which is a fact about the trial populations rather than the drugs. On the one measure both labels report identically — any gastrointestinal adverse reaction — the excess over placebo is 26 points on both, and the proportion who discontinued because of it is 4.3% on both at the top dose. The real asymmetry is that the Zepbound label adds that the reactions "decreased over time" and no semaglutide label makes that claim.
Is the Wegovy FlexTouch cheaper than the single-dose pens?: This page will not say, because the file it uses does not price it. The CMS NADAC file dated 2026-09-16 contains rows for every Wegovy single-dose pen strength and for the Wegovy tablets, and no row for the 9.6 mg/3 mL FlexTouch. For Zepbound the comparison can be made and it is large: a month at 15 mg is $1,139 in single-dose pens and $728 from a KwikPen. It would be reasonable to expect a four-dose Wegovy device to behave similarly, and expecting is not the same as knowing, so the figure is left blank rather than estimated from the pen rate.
Can a teenager take either of these?: Wegovy injection, yes; Zepbound, no. Wegovy is indicated "to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity". Zepbound's Use in Specific Populations section contains a single sentence on the question: "The safety and effectiveness of ZEPBOUND have not been established in pediatric patients." That is not a soft signal or a matter of prescriber discretion over dose — there is no paediatric Zepbound data in the label at all, and for an adolescent the two products are not alternatives.
Is 2.4 mg of Wegovy the same as 15 mg of Zepbound?: They are both the top of their own ladder and that is the only sense in which they correspond. No label, trial or guideline states a milligram equivalence between semaglutide and tirzepatide, and the ratio between the two ladder tops is an artefact of two companies picking round numbers. Both take the same 21 weeks to climb, if you climb all the way: Wegovy reaches 2.4 mg at week 17 and the 7.2 mg high dose at week 21, while Zepbound reaches 15 mg at week 21 at the earliest. If you switch, the new product starts at its own starting dose and nothing about your old dose carries across.
Can I get Zepbound in a vial and Wegovy in a vial?: Zepbound yes, Wegovy no. The Zepbound How Supplied section lists "4 pre-filled single-dose pens, 1 single-dose vial, 4 single-dose vials, 1 multi-dose vial, or 1 single-patient-use KwikPen". The Wegovy section lists "4 single-dose pens, 4 single-dose syringes with integrated needles, or 1 single-patient-use pen (WEGOVY FlexTouch)" — pens and prefilled syringes, no vial of any kind. If you have been offered a vial of semaglutide it is not branded Wegovy, and whether it is a legitimate product at all is a different question with a different answer.
Do both carry the same warning?: The boxed warning is the same on both: the risk of thyroid C-cell tumours seen in rodents, with a contraindication in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Below the box the lists diverge in detail rather than in kind — pancreatitis, gallbladder disease, acute kidney injury from dehydration, hypoglycaemia with insulin secretagogues, and the shared instruction that neither should be combined with any other GLP-1 receptor agonist. Both labels also state that the escalation schedule exists specifically "to reduce the risk of gastrointestinal adverse reactions", which is the reason not to rush it.

Sources

Next steps

Compare online weight-loss providersWhich platforms prescribe branded Wegovy or Zepbound, which dispense compounded, and what each charges.Medical weight loss, start to finishEligibility, the first six months, monitoring, and what happens if you stop.

Other comparisons

Educational reference, not medical advice. Which medication suits you is a decision for your prescriber.